TAK 906

Drug Profile

TAK 906

Alternative Names: TAK-906

Latest Information Update: 25 Jul 2017

Price : $50

At a glance

  • Originator Takeda Oncology
  • Class
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastroparesis

Most Recent Events

  • 10 Jul 2017 Takeda completes a phase I trial in Healthy volunteers in USA (NCT03161405)
  • 26 May 2017 Phase-I clinical trials in Gastroparesis (In volunteers) in USA (PO) (NCT03161405)
  • 25 May 2017 Takeda Oncology plans a phase I trial in Healthy volunteers (NCT03161405)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top